※Sunovion Announces Utibron Neohaler Inhalation Powder Data Showing Lung Function and Health-Related Quality of Life Improvement in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
- Presentations at the American Thoracic Society 2017 International Conference (ATS 2017) also included long-term safety data and pooled analyses of pivotal studies -
May 23, 2017
MARLBOROUGH, Mass.--(BUSINESS WIRE)--
Sunovion Pharmaceuticals Inc. (Sunovion) announced that multiple data analyses from two Phase 3 studies demonstrating that Utibron Neohaler inhalation powder improved lung function, health-related quality of life (HRQL),
dyspnea and night-time symptoms compared to placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), were presented at the 2017 American Thoracic Society International Conference (ATS 2017) held May 19-24, 2017, in Washington, D.C.
Findings from the FLIGHT1 and FLIGHT2 pivotal efficacy and safety studies, as well as from the FLIGHT3 long-term safety study, were included in nine posters for UTIBRON NEOHALER presented at the meeting.
UTIBRON NEOHALER is a twice-daily combination long-acting beta2 agonist (indacaterol) and long-acting muscarinic antagonist (glycopyrrolate) (LABA/LAMA) for the long-term maintenance treatment of airflow obstruction in people with COPD, including chronic bronchitis and/or emphysema.
UTIBRON NEOHALER is not indicated to treat asthma or for the relief of sudden symptoms of COPD.
“Improvement in health related quality of life, including reduction of difficult or labored breathing, is a key therapeutic goal for patients with COPD that is reflected in the updated 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report,”
said lead investigator of FLIGHT1 and FLIGHT2 studies Donald A. Mahler, M.D., Emeritus Professor of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, N.H.
“These UTIBRON NEOHALER data show that the dual bronchodilator significantly improves and sustains bronchodilation and may improve health status and COPD symptoms in moderate-to-severe patients.”
“UTIBRON NEOHALER has demonstrated the value of dual bronchodilation treatment for people living with COPD,” said Thomas H. Goodin, Ph.D., Senior Director, Clinical Development at Sunovion.
“The data presented at ATS indicate that UTIBRON NEOHALER was associated with statistically significant and clinically important improvements in lung function as well as a reduction in the number of sleep disturbances and in the use of rescue medication, which may have a positive impact on patients’ quality of life.”
***
※Sunovion Announces Utibron Neohaler Inhalation Powder Data Showing Lung Function and Health-Related Quality of Life Improvement in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
- Presentations at the American Thoracic Society 2017 International Conference (ATS 2017) also included long-term safety data and pooled analyses of pivotal studies -
May 23, 2017
MARLBOROUGH, Mass.--(BUSINESS WIRE)--
Sunovion Pharmaceuticals Inc. (Sunovion) announced that multiple data analyses from two Phase 3 studies demonstrating that Utibron Neohaler inhalation powder improved lung function, health-related quality of life (HRQL),
dyspnea and night-time symptoms compared to placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), were presented at the 2017 American Thoracic Society International Conference (ATS 2017) held May 19-24, 2017, in Washington, D.C.
Findings from the FLIGHT1 and FLIGHT2 pivotal efficacy and safety studies, as well as from the FLIGHT3 long-term safety study, were included in nine posters for UTIBRON NEOHALER presented at the meeting.
UTIBRON NEOHALER is a twice-daily combination long-acting beta2 agonist (indacaterol) and long-acting muscarinic antagonist (glycopyrrolate) (LABA/LAMA) for the long-term maintenance treatment of airflow obstruction in people with COPD, including chronic bronchitis and/or emphysema.
UTIBRON NEOHALER is not indicated to treat asthma or for the relief of sudden symptoms of COPD.
“Improvement in health related quality of life, including reduction of difficult or labored breathing, is a key therapeutic goal for patients with COPD that is reflected in the updated 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report,”
said lead investigator of FLIGHT1 and FLIGHT2 studies Donald A. Mahler, M.D., Emeritus Professor of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, N.H.
“These UTIBRON NEOHALER data show that the dual bronchodilator significantly improves and sustains bronchodilation and may improve health status and COPD symptoms in moderate-to-severe patients.”
“UTIBRON NEOHALER has demonstrated the value of dual bronchodilation treatment for people living with COPD,” said Thomas H. Goodin, Ph.D., Senior Director, Clinical Development at Sunovion.
“The data presented at ATS indicate that UTIBRON NEOHALER was associated with statistically significant and clinically important improvements in lung function as well as a reduction in the number of sleep disturbances and in the use of rescue medication, which may have a positive impact on patients’ quality of life.”